Ezrin in Cancer:

1.    A Ghaffari, V Hoskin, G Mullins, P Greer, F Kiefer, Y Madarnas, S SenGupta, BE Elliott. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Res. 2019 Jan 24;21(1):12

2.    A Ghaffari, N Peterson, K Khalaj, A Robinson, JA Francis, M Koti. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer, 2018, 119(4):440-449.

3.    Gulisa Turashvili, Elizabeth D. Lightbody, Kathrin Tyryshkin, Sandip K. SenGupta, Bruce E. Elliott, Yolanda Madarnas, Abdi Ghaffari, Andrew Day, Christopher JB Nicol. Novel prognostic and predictive microRNA targets for triple negative breast cancer. FASEB J. 2018 May 29.

4.    Azad T, Janse van Rensburg HJ, Lightbody ED, Neveu B, Champagne A, Ghaffari A, Kay VR, Hao Y, Shen H, Yeung B, Croy BA, Guan KL, Pouliot F, Zhang J, Nicol CJB, Yang X. LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nature Communication, 2018, 9(1):1061.

5.    V. Hoskin, A. Szeto, A. Ghaffari, S. Organ, G. Cote and B.E. Elliott. Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer invasion. Mol. Biol. Cell 2015;26(19):3464-79.

6.    GhaffariA; Hoskin V; Szeto A.; Hum M; Liaghati N.; Nakatsu K; Madarnas Y.; SenGupta S.; Elliott B.E. A novel role for ezrin in breast cancer angio/lymphangiogenesis. Breast Cancer Research 2014 16:438.